Literature DB >> 28839962

Optimized local therapy for locally advanced non-small cell lung cancer.

Charlotte Billiet1,2, Dirk De Ruysscher1,3.   

Abstract

Entities:  

Year:  2017        PMID： 28839962      PMCID： PMC5542966          DOI： 10.21037/jtd.2017.06.77

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.

Authors:  Miklos Pless; Roger Stupp; Hans-Beat Ris; Rolf A Stahel; Walter Weder; Sandra Thierstein; Marie-Aline Gerard; Alexandros Xyrafas; Martin Früh; Richard Cathomas; Alfred Zippelius; Arnaud Roth; Milorad Bijelovic; Adrian Ochsenbein; Urs R Meier; Christoph Mamot; Daniel Rauch; Oliver Gautschi; Daniel C Betticher; René-Olivier Mirimanoff; Solange Peters
Journal:  Lancet       Date:  2015-08-11       Impact factor: 79.321

2.  Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection.

Authors:  Charlotte Billiet; Stéphanie Peeters; Herbert Decaluwé; Johan Vansteenkiste; Christophe Dooms; Christophe M Deroose; Marc Hendrikx; Paul De Leyn; Paul Bulens; Rezaul Karim; Cécile Le Péchoux; Jeroen Mebis; Dirk De Ruysscher
Journal:  J Thorac Oncol       Date:  2016-07-05       Impact factor: 15.609

3.  Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer.

Authors:  Michael Thomas; Christian Rübe; Petra Hoffknecht; Hans N Macha; Lutz Freitag; Albert Linder; Norman Willich; Michael Hamm; Gerhard W Sybrecht; Dieter Ukena; Karl-Matthias Deppermann; Cornelia Dröge; Dorothea Riesenbeck; Achim Heinecke; Cristina Sauerland; Klaus Junker; Wolfgang E Berdel; Michael Semik
Journal:  Lancet Oncol       Date:  2008-06-24       Impact factor: 41.316

Review 4.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

Authors:  Anne Aupérin; Cecile Le Péchoux; Estelle Rolland; Walter J Curran; Kiyoyuki Furuse; Pierre Fournel; Jose Belderbos; Gerald Clamon; Hakki Cuneyt Ulutin; Rebecca Paulus; Takeharu Yamanaka; Marie-Cecile Bozonnat; Apollonia Uitterhoeve; Xiaofei Wang; Lesley Stewart; Rodrigo Arriagada; Sarah Burdett; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

5.  Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

Authors:  Jan P van Meerbeeck; Gijs W P M Kramer; Paul E Y Van Schil; Catherine Legrand; Egbert F Smit; Franz Schramel; Vivianne C Tjan-Heijnen; Bonne Biesma; Channa Debruyne; Nico van Zandwijk; Ted A W Splinter; Giuseppe Giaccone
Journal:  J Natl Cancer Inst       Date:  2007-03-21       Impact factor: 13.506

Review 6.  2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.

Authors:  W E E Eberhardt; D De Ruysscher; W Weder; C Le Péchoux; P De Leyn; H Hoffmann; V Westeel; R Stahel; E Felip; S Peters
Journal:  Ann Oncol       Date:  2015-04-20       Impact factor: 32.976

7.  Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.

Authors:  Daniel C Betticher; Shu-Fang Hsu Schmitz; Martin Tötsch; Eva Hansen; Christine Joss; Christian von Briel; Ralph A Schmid; Miklos Pless; James Habicht; Arnaud D Roth; Anastase Spiliopoulos; Rolf Stahel; Walter Weder; Roger Stupp; Fritz Egli; Markus Furrer; Hanspeter Honegger; Martin Wernli; Thomas Cerny; Hans-Beat Ris
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

8.  Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.

Authors:  N Martini; M G Kris; B J Flehinger; R J Gralla; M S Bains; M E Burt; R Heelan; P M McCormack; K M Pisters; J R Rigas
Journal:  Ann Thorac Surg       Date:  1993-06       Impact factor: 4.330

9.  Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

Authors:  Wilfried Ernst Erich Eberhardt; Christoph Pöttgen; Thomas Christoph Gauler; Godehard Friedel; Stefanie Veit; Vanessa Heinrich; Stefan Welter; Wilfried Budach; Werner Spengler; Martin Kimmich; Berthold Fischer; Heinz Schmidberger; Dirk De Ruysscher; Claus Belka; Sebastian Cordes; Rodrigo Hepp; Diana Lütke-Brintrup; Nils Lehmann; Martin Schuler; Karl-Heinz Jöckel; Georgios Stamatis; Martin Stuschke
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

10.  Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.

Authors:  Kai-Lin Yang; Yih-Chen Chang; Hui-Ling Ko; Mau-Shin Chi; Hsin-Ell Wang; Pei-Sung Hsu; Chen-Chun Lin; Diana Yu-Wung Yeh; Shang-Jyh Kao; Jiunn-Song Jiang; Kwan-Hwa Chi
Journal:  Clin Lung Cancer       Date:  2016-06-08       Impact factor: 4.785
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.